Letters
Screening for hepatitis C
Authors’ reply to Selvapatt and colleagues, Matthews and colleagues, Badrinath, and Ward and Lee
BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h674 (Published 24 February 2015) Cite this as: BMJ 2015;350:h674
- Ronald L Koretz, emeritus professor of clinical medicine1,
- Kenneth W Lin, associate professor of family medicine2,
- John P A Ioannidis, professor of medicine3,
- Jeanne Lenzer, medical investigative journalist4
- 1David Geffen-UCLA School of Medicine, CA, USA
- 2Georgetown University School of Medicine, Washington, DC, USA
- 3Stanford University, CA, USA
- 4New York, USA
- jeanne.lenzer{at}gmail.com
Selvapatt and colleagues made several points: large numbers of people are infected; birth cohort screening is cost effective; previously treated patients without severe fibrosis are unlikely to progress; sustained virological response improves quality of life; treatment reduces mortality; and newer agents have fewer side effects (last two also alluded to by Matthews and colleagues).1 2 3 The number of patients is not the issue, which is whether …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £138 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£23 / $37 / €30 (inc. VAT)
You can download a PDF version for your personal record.